These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22031835)

  • 1. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro.
    Abdel-Motal UM; Sarkis PT; Han T; Pudney J; Anderson DJ; Zhu Q; Marasco WA
    PLoS One; 2011; 6(10):e26473. PubMed ID: 22031835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer.
    Abdel-Motal UM; Harbison C; Han T; Pudney J; Anderson DJ; Zhu Q; Westmoreland S; Marasco WA
    Gene Ther; 2014 Sep; 21(9):802-10. PubMed ID: 24965083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.
    Mantis NJ; Palaia J; Hessell AJ; Mehta S; Zhu Z; Corthésy B; Neutra MR; Burton DR; Janoff EN
    J Immunol; 2007 Sep; 179(5):3144-52. PubMed ID: 17709529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier.
    Nazli A; Dizzell S; Zahoor MA; Ferreira VH; Kafka J; Woods MW; Ouellet M; Ashkar AA; Tremblay MJ; Bowdish DM; Kaushic C
    Cell Mol Immunol; 2019 Feb; 16(2):178-194. PubMed ID: 29553138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro.
    Devito C; Ellegård R; Falkeborn T; Svensson L; Ohlin M; Larsson M; Broliden K; Hinkula J
    Sci Rep; 2018 Jul; 8(1):10180. PubMed ID: 29977063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
    Brady JM; Baltimore D; Balazs AB
    Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
    Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
    Front Immunol; 2021; 12():670561. PubMed ID: 35003053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
    Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
    PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.
    Furuta Y; Eriksson K; Svennerholm B; Fredman P; Horal P; Jeansson S; Vahlne A; Holmgren J; Czerkinsky C
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12559-63. PubMed ID: 7809077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
    Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
    Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
    Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
    J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.
    Veazey RS; Shattock RJ; Pope M; Kirijan JC; Jones J; Hu Q; Ketas T; Marx PA; Klasse PJ; Burton DR; Moore JP
    Nat Med; 2003 Mar; 9(3):343-6. PubMed ID: 12579198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.
    Liu Q; Zhang P; Miao H; Lin Y; Kwon YD; Kwong PD; Rikhtegaran-Tehrani Z; Seaman MS; DeVico AL; Sajadi MM; Lusso P
    J Virol; 2021 May; 95(12):. PubMed ID: 33827946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
    Seaton KE; Ballweber L; Lan A; Donathan M; Hughes S; Vojtech L; Moody MA; Liao HX; Haynes BF; Galloway CG; Richardson BA; Karim SA; Dezzutti CS; McElrath MJ; Tomaras GD; Hladik F
    PLoS One; 2014; 9(7):e101863. PubMed ID: 25054205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.